ScreenerHero

YCBDcbdMD, Inc.

AMEX · US · Healthcare · Drug Manufacturers - Specialty & Generic · cbdmd.com
0.5089USD+0.77%Mkt Cap: 5.70M $P/E: 2.21

cbdMD, Inc. produces and distributes various cannabidiol (CBD) products in the United States and internationally. The company owns and operates various consumer hemp-based CBD brands. Its cbdMD brand products include oil…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap5.70M $
Enterprise Value5.80M $
Revenue (TTM)20.93M $
Gross Profit11.97M $
Net Income (TTM)-2.04M $
Revenue/Share2.146 USD
Last Price0.5089 USD
Fiscal Year EndSep 2025
MR QuarterJun 2026
Employees42
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)2.21
P/E (Forward)-0.57
PEG—
EV/EBITDA-3.08
EV/Revenue0.28
P/S0.27
P/B0.66
EPS (TTM)0.23
EPS (Forward)-0.89
52W Range
0.46512% of range2.560
52W High2.560 USD
52W Low0.4651 USD
Profitability
Gross Margin62.37%
Oper. Margin-20.36%
EBITDA Margin-9.01%
Profit Margin-10.63%
ROE-28.24%
ROA-19.59%
Growth
Revenue Growth20.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.45M $
CapEx (TTM)184.17K $
FCF Margin-5.03%
FCF Yield-18.46%
Net Debt93.92K $
Net Debt/EBITDA-0.05
Balance Sheet
Debt/Equity0.11
Current Ratio2.50
Quick Ratio1.26
Book Value/Sh0.7730 USD
Cash/Share0.1890 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:8
Split DateMay 7, 2025
Analyst Consensus
Rating3.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.11.21M
Float10.91M
Insiders10.00%
Institutions8.19%
Short Interest
Short Ratio2.3d
Short % Float5.37%
Short % Out.5.03%
Shares Short527.70K
Short (prev mo.)550.10K
Technical
SMA 500.6135 (-17.0%)
SMA 2000.7948 (-36.0%)
Beta2.17
S&P 52W Chg19.18%
Avg Vol (30d)224.69K
Avg Vol (10d)192.85K
Technical Indicators
RSI (14)40.9
MACD-0.0311
MACD Signal-0.0306
MACD Hist.-0.0005
BB Upper0.6152 USD
BB Middle0.5331 USD
BB Lower0.4509 USD
BB Width30.82%
ATR (14)0.0436 USD
Vol Ratio (20d)0.71x